We are in the early days of a short, but intense consulting project involving the Russian pharmaceutical market. It's a very interesting market, with some notable differences when compared…
The coverage of the announced negotiation by Sanofi to divest its European generics business triggered this cranky post. I don’t quite understand why so many journalists/analysts negatively criticize management when…
Last week, an FDA Advisory committee unanimously recommended the approval of Epidiolex for the treatment of two rare forms of pediatric epilepsy (Lennox-Gastaut syndrome and Dravet syndrome). The full…
Last week was the 20th anniversary of the launch of Viagra (sildenafil, Pfizer). Formerly known as UK-92,480, sildenafil was first synthesized at Pfizer's faculty in Kent, UK. The press…
Last week was another jam-packed week of meetings, this time at BIO-Europe Spring in Amsterdam. It is only our third appearance at this event, having participated in previous BIO…
PWC recently published their 12th annual Top Health Industry Issues report for 2018. The twelve issues in the report run the gamut...from pricing to natural disasters to reform. It's an…
Following up on their sobering report on drug development in depression, BIO has released another report in their State of Innovation in Highly Prevalence Chronic Diseases series. This time,…
If you have nothing better to do on a cold Winter’s day, try researching the links between bacteria and cancer. Want more? Try researching the links between bacteria and a…
Last week, BIO published an exceedingly interesting report, entitled The State of Innovation in Highly Prevalent Chronic Diseases: Depression Therapeutics. The press release and report are available here. This and…
Dr. Eric Topol recently posted an interesting image on Twitter. According the US Bureau of Labor Statistics, Healthcare jobs exceeded Retail jobs: We believe this is unsustainable, as…